Amphetamine News and Research RSS Feed - Amphetamine News and Research

Neurovance closes $6.3M extension to its series A1 financing round to advance development of EB-1020 SR

Neurovance closes $6.3M extension to its series A1 financing round to advance development of EB-1020 SR

Neurovance, Inc. today announced that it has closed a $6.3 million extension to its series A1 financing round to further advance development of EB-1020 SR, a non-stimulant, for the treatment of all subtypes of adult ADHD (attention deficit hyperactivity disorder). [More]
Chemists able to trace narcotics substances, prescription drugs in Swedish wastewater

Chemists able to trace narcotics substances, prescription drugs in Swedish wastewater

Chemists at Ume- University in Sweden have been able to trace narcotics substances and prescription drugs in measurements of wastewater from 33 Swedish sewage treatment plants. Cocaine, amphetamine, and methamphetamine, in measurable concentrations, were found in a total of half of the locations. [More]
Research highlights value of fathers in both neurobiology and behavior of offspring

Research highlights value of fathers in both neurobiology and behavior of offspring

Even with today's technology, it still takes both a male and a female to make a baby. But is it important for both parents to raise that child? Many studies have outlined the value of a mother, but few have clearly defined the importance of a father, until now. [More]
High doses of ADHD drugs may be effective for people with amphetamine dependency

High doses of ADHD drugs may be effective for people with amphetamine dependency

People with ADHD and dependency rarely respond as they should to ADHD drugs. A randomised study from Karolinska Institutet in Sweden now shows that it is possible to obtain the desired efficacy by administering the drug in higher doses. [More]
Study proposes novel treatment for narcolepsy

Study proposes novel treatment for narcolepsy

Lancet Neurology, a prestigious journal in its domain, publishes in its last issue, an article entitled "Pitolisant versus placebo and modafinil in patients with narcolepsy: a double-blind randomised trial" authored by Y. Dauvilliers and others from the HARMONY I study group which proposes a novel treatment for this orphan disease. It is accompanied by a Commentary entitled "A need for new treatments in narcolepsy". [More]

Study looks at attitudes toward drug use among high school seniors

High school seniors who frown upon the use of drugs are most likely to be female, nonsmokers or hold strong religious beliefs, according to a study- by Joseph Palamar of New York University. Palamar examines how teenagers' attitudes toward marijuana influenced their thoughts on the further use of other illicit drugs. [More]
ERK pathway discovery may provide therapeutic options for treating drug addictions

ERK pathway discovery may provide therapeutic options for treating drug addictions

The extracellular-signal regulated kinase (ERK) pathway plays a role in multiple drug addictions and appears to modulate neuronal plasticity through epigenetic mechanisms, say French scientists. [More]

New website aims to reduce negative impact of amphetamine use

Reducing the negative impact of amphetamine use is the aim of a new website launched by a Griffith University PhD candidate, in the face of this significant drug problem. [More]
Caffeine-laden energy drinks pose hazards to adolescents

Caffeine-laden energy drinks pose hazards to adolescents

Parents beware. If your tots and teens get their hands on your energy drinks, they could experience seizures, heart palpitations or other problems that drive them to the hospital emergency room. [More]
Opioid dependence causes greatest health burden of all illicit drugs

Opioid dependence causes greatest health burden of all illicit drugs

The first ever analysis of the global and regional prevalence of dependence upon the four major categories of illicit drugs – amphetamine, cannabis, cocaine, and opioids (such as heroin) – has revealed that opioid dependence causes the greatest health burden (overall death and illness) of all the illicit drugs. The results come from new analysis of the Global Burden of Disease Study 2010, and are published in The Lancet. [More]
Scientists report possible basis for why food-restricted animals show susceptibility to drugs of abuse

Scientists report possible basis for why food-restricted animals show susceptibility to drugs of abuse

Scientists today reported a possible basis for why food-restricted animals show increased susceptibility to drugs of abuse. This association has puzzled researchers since it was first observed more than three decades ago. [More]
Study finds that long-term cannabis use affects motivation

Study finds that long-term cannabis use affects motivation

Long-term cannabis users tend to produce less dopamine, a chemical in the brain linked to motivation, a study has found. [More]
Cannabis users appear to lack motivation

Cannabis users appear to lack motivation

Researchers found that dopamine levels in a part of the brain called the striatum were lower in people who smoke more cannabis and those who began taking the drug at a younger age. [More]

Highland Therapeutics subsidiary reports positive HLD-200 Phase-1 results in ADHD patients

Highland Therapeutics, Inc., a specialty pharmaceutical company based in the MaRS Discovery District in Toronto, today announced that its wholly owned subsidiary has generated positive Phase-1 results for HLD-200 - a novel formulation of methylphenidate being developed to treat the symptoms associated with Attention-Deficit/Hyperactivity Disorder. [More]

Review on new, hazardous drugs of abuse presented in Journal of Addiction Medicine

The last few years have seen the emergence of a new drug problem in so-called "bath salts"-actually "designer stimulants," packaged and sold in ways that skirt drug laws. A review and update on these designer drugs is presented in the June Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine. [More]
Lightlake Therapeutics announces Phase II clinical trial results of nasal spray treatment for BED

Lightlake Therapeutics announces Phase II clinical trial results of nasal spray treatment for BED

Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial. [More]

New U-M poll shows 1 in 100 parents believe their kids use prescription stimulants to boost grades

As high schoolers prepare for final exams, teens nationwide may be tempted to use a "study drug" -- a prescription stimulant or amphetamine -- to gain an academic edge. But a new University of Michigan poll shows only one in 100 parents of teens 13-17 years old believes that their teen has used a study drug. [More]
Students receive Addiction Science Award at 2013 Intel International Science and Engineering Fair

Students receive Addiction Science Award at 2013 Intel International Science and Engineering Fair

An exploration of electronic "screen time" and sleep on mood, memory and learning was given the top Addiction Science Award at the 2013 Intel International Science and Engineering Fair - the world's largest science competition for high school students. [More]

Lightlake to present Phase II clinical trial results of opioid antagonist nasal spray at APA Annual Meeting

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing addiction treatments, announced today that a scientific abstract based on results of the Company's Phase II clinical trial of its opioid antagonist nasal spray treatment for patients with Binge Eating Disorder has been accepted for presentation at the American Psychiatric Association Annual Meeting taking place in San Francisco, California, May 18-22, 2013. [More]
New research may shed light on alcohol addiction vulnerability in some people

New research may shed light on alcohol addiction vulnerability in some people

A Wake Forest Baptist Medical Center team studying alcohol addiction has new research that might shed light on why some drinkers are more susceptible to addiction than others. [More]